Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,417

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,417 results for “triple negative breast cancer”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

ClinicalTrials.gov study NCT02341911. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Reverse Triple Negative Immune Resistant Breast Cancer

ClinicalTrials.gov study NCT05076682. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatme

ClinicalTrials.gov study NCT05404321. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

ClinicalTrials.gov study NCT07299409. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

ClinicalTrials.gov study NCT06793332. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

ClinicalTrials.gov study NCT01623349. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

ClinicalTrials.gov study NCT05491083. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Pre-operative Zoledronate in Triple Negative Breast Cancer

ClinicalTrials.gov study NCT02347163. IPD Sharing: NO. Countries: 1. Publications: 16.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

ClinicalTrials.gov study NCT04799249. IPD Sharing: Not stated. Countries: 11. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov study NCT05742269. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

ClinicalTrials.gov study NCT03154749. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

ClinicalTrials.gov study NCT02978495. IPD Sharing: UNDECIDED. Countries: 1. Publications: 9.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

ClinicalTrials.gov study NCT02993094. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residua

ClinicalTrials.gov study NCT03818685. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial

ClinicalTrials.gov study NCT05763992. IPD Sharing: NO. Countries: 1. Publications: 15.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer

ClinicalTrials.gov study NCT03457779. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer

ClinicalTrials.gov study NCT03164993. IPD Sharing: NO. Countries: 2. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

ClinicalTrials.gov study NCT01642771. IPD Sharing: Not stated. Countries: 1. Publications: 9.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

ClinicalTrials.gov study NCT02833766. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

ClinicalTrials.gov study NCT05347134. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record